An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis

References

1. Barry C. E. 3rd, Slayden R. A, Sampson A. E., Lee R. E. 2000; Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59:221–231
   [Google Scholar]
2. Cole S. T, Brosch R, Parkhill J. 39 other authors 1998; Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544
   [Google Scholar]
3. Crowle A. J, Sbarbaro J. A., May M. H. 1986; Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 134:1052–1055
   [Google Scholar]
4. Dye C, Scheele S, Dolin P, Pathania V., Raviglione M. C. 1999; Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (J Am Med Assoc) 282:677–686
   [Google Scholar]
5. Espinal M. A, Laszlo A, Simonson L. 9 other authors 2001; Global trends in resistance to antituberculosis drugs. World Health Organization–International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344:1294–1303
   [Google Scholar]
6. Flynn J. L., Chan J. 2001; Immunology of tuberculosis. Annu Rev Immunol 19:93–129
   [Google Scholar]
7. Glickman M. S., Jacobs W. R. Jr 2001; Microbial pathogenesis of Mycobacterium tuberculosis : dawn of a discipline. Cell 104:477–485
   [Google Scholar]
8. Global Alliance for TB Drug Development 2001; Scientific blueprint for tuberculosis drug development. Tuberculosis 81: Suppl 11–52
   [Google Scholar]
9. Heifets L., Lindholm-Levy P. 1992; Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223–1225
   [Google Scholar]
10. Heifets L, Higgins M., Simon B. 2000; Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4:491–495
    [Google Scholar]
11. Klemens S. P, Sharpe C. A., Cynamon M. H. 1996; Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob Agents Chemother 40:14–16
    [Google Scholar]
12. McKinney J. D. 2000; In vivo veritas : the search for TB drug targets goes live. Nat Med 6:1330–1333
    [Google Scholar]
13. Meighen E. 1991; Molecular biology of bacterial luminescence. Microbiol Rev 55:123–142
    [Google Scholar]
14. Mitchison D. A. 1985; The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219–225
    [Google Scholar]
15. Orme I. M., Collins F. M. 1994; Mouse model of tuberculosis. In Tuberculosis: Pathogenesis, Protection and Control pp 113–134 Edited by Bloom B. R. Washington, DC: American Society for Microbiology;
    [Google Scholar]
16. Russell D. G. 2001; Mycobacterium tuberculosis : here today, and here tomorrow. Nat Rev Mol Cell Biol 2:569–577
    [Google Scholar]
17. Snewin V. A, Gares M. P, Gaora P. O, Hasan Z, Brown I. N., Young D. B. 1999; Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67:4586–4593
    [Google Scholar]
18. Wilson M, DeRisi J, Kristensen H. H, Imboden P, Rane S, Brown P. O., Schoolnik G. K. 1999; Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 96:12833–12838
    [Google Scholar]